Pentaxim® Vaccine
MRP ₹ 3,145
Pentaxim® vaccine is used to protect against infectious diseases. It is indicated to protect child against diphtheria, pertussis, tetanus, poliomyelitis and invasive infections caused by Haemophilus influenzae type b bacterium (such as meningitis, blood poisoning, etc). The vaccine works by developing body’s defense mechanism to protect against these diseases. Pentaxim® is indicated in children from the age of 2 months.
DESCRIPTION
Pentaxim® is available in the form of 0.5mL prefilled syringe with cloudy, whitish, sterile suspension and a vial of white powder. After reconstitution the suspension becomes cloudy and whitish and must be used immediately. Pentaxim® contains (DTaP-IPV vaccine) - diphtheria, tetanus and pertussis toxoid, filamentous hemaggluttinin, inactivated type 1, 2 and 3 poliovirus D antigen and the (Hib vaccine) contains lyophilized powder of polyribosylribitol phosphate (PRP) chemically conjugated to tetanus toxoid (PRP⁓T) to be reconstituted in DTaP-IPV vaccine for use.
Pentaxim® is administered as intramuscular injection in the antero-lateral side of the thigh (middle third) in infants and in the upper arm in children.
Pentaxim® is currently used in more than 100 countries with greater than 87 million doses distributed worldwide. Vaccine composition and quality of Pentaxim® meets the European Union Pharmacopoeia requirements and is produced in accordance with good manufacturing practices.1
CLINICAL INFORMATION2
Pentaxim® is approved to be used in children from the age of 2 months.
Dosing frequency of Pentaxim®
STORAGE AND HANDLING
Store at 2°C to 8°C (35°F to 46°F). DO NOT FREEZE. Do not use if you notice an abnormal colour or the presence of foreign particles. Do not use after expiration date shown on the label.
| Vaccination type | Dosing interval |
|---|---|
| Primary vaccination | Three injections administered at an interval of one or two months from 2 months of age |
| Booster vaccination | One year after the primary vaccination during the second year of life |
References: 1. Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP-IPV//PRP approximately T vaccine (Pentaxim®): a review of 16 years' clinical experience. Expert review of vaccines. Jul 2011;10(7):981-1005. 2. Pentaxim® vaccine [Prescribing information]. Sanofi Pasteur Inc.